A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy (NCT06132893)
A Phase 2/3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy, Safety and Tolerability of BHV-7000 in Subjects With Refractory Focal Onset Epilepsy
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to determine whether BHV-7000 is effective in the treatment of refractory focal epilepsy.
Who can join: Review the eligibility criteria below.
Location: Barrow Neurological Institute — Phoenix, Arizona
Age range: 18 Years to 75 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (124 Sites)
Showing the first 25 of 124 sites.
- Barrow Neurological Institute — Phoenix, Arizona
- Center for Neurosciences — Tucson, Arizona
- Clinical Trials, Inc. — Little Rock, Arkansas
- WRN — Rogers, Arkansas
- University of California San Diego — La Jolla, California
- University of California, Los Angeles — Los Angeles, California
- Stanford Health Care — Palo Alto, California
- Profound Research LLC — Pasadena, California
- University of Colorado Anschultz Medical Campus — Aurora, Colorado
- Yale School of Medicine - Yale-New Haven Hospital — New Haven, Connecticut
- EZR Research LLC — Boca Raton, Florida
- Nova Clinical Research, LLC — Bradenton, Florida
- University of Florida (Jacksonville) — Jacksonville, Florida
- University of Miami — Miami, Florida
- Floridian Research Institute — Miami, Florida
- AdventHealth Orlando — Orlando, Florida
- Medsol Clinical Research Center — Port Charlotte, Florida
- Santos Research Center — Tampa, Florida
- Encore Medical Research of Weston LLC. — Weston, Florida
- Pediatrix Medical Group of Florida — Winter Park, Florida
- Augusta University — Augusta, Georgia
- Hawaii Pacific Neuroscience — Honolulu, Hawaii
- Consultants in Epilepsy & Neurology, PLLC — Boise, Idaho
- Northwestern University — Chicago, Illinois
- Revive Research Institute, Inc. — Elgin, Illinois
📞 Contact the Study Coordinator
Phone: (203) 404-0410
Email: clinicaltrials@biohavenpharma.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Focal Epilepsy
- Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy — Peoria, Arizona
- A Study to Evaluate XEN1101 as Adjunctive Therapy in Focal Epilepsy — Birmingham, Alabama
- Randomized Clinical Trial Evaluating the Efficacy and Safety of Vormatrigine in Adults With Focal Seizures — Miami, Florida
- Breathing Rescue for SUDEP Prevention — Houston, Texas
- A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures — Boise, Idaho
- Study of Transcranial Direct Current Stimulation to Treat Epilepsy — Rochester, Minnesota
Explore by condition: All Focal Epilepsy clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.